Skip to main content
COLLEGIUM PHARMACEUTICAL, INC logo

COLLEGIUM PHARMACEUTICAL, INC — Investor Relations & Filings

Ticker · COLL ISIN · US19459J1043 LEI · 54930049FXZMTLW8D496 US Manufacturing
Open in API
Filings indexed 821 across all filing types
Latest filing 2025-05-19 Director's Dealing
Country US United States of America
Listing US COLL

About COLLEGIUM PHARMACEUTICAL, INC

https://www.collegiumpharma.com/

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company that develops and commercializes medicines for people with serious medical conditions. The company is focused on building a portfolio of differentiated medications. Its primary area of expertise is in pain management, where it develops products with abuse-deterrent properties designed to be safer alternatives for patients and the community.

Recent filings

Filing Released Lang Actions
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2025-05-19 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about the 2025 Annual Meeting of Shareholders, voting results on various proposals including election of directors, approval of executive compensation, ratification of auditors, and approval of an equity incentive plan. These are official results from shareholder votes at a general meeting. The document is not a full annual report, audit report, or proxy statement, but specifically reports the voting outcomes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (7091 characters) and detailed voting tables support this classification with high confidence.
2025-05-19 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-14 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content specifically details the execution of an accelerated share repurchase agreement (ASR) by Collegium Pharmaceutical, including the amount, shares involved, and terms of the agreement. This is a clear update on the company's share repurchase activity, which relates to capital structure changes and financing activities. The document is not a full financial report, earnings release, or management discussion, but rather a specific announcement about a capital transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a confident classification.
2025-05-12 English
10-Q
Interim / Quarterly Report Q1 2025
2025-05-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 8, 2025, for Collegium Pharmaceutical, Inc. It reports the issuance of a press release announcing quarterly financial results for the period ended March 31, 2025, and an earnings presentation. The document itself does not contain the financial results or detailed financial statements but rather furnishes these materials as exhibits. The length is 3743 characters, which is relatively short and consistent with a current report filing that announces or furnishes other documents rather than being a full financial report. The key section is Item 2.02 Results of Operations and Financial Condition, which typically corresponds to an earnings release. The press release is attached as Exhibit 99.1 and the earnings presentation as Exhibit 99.2. Since the document is a Form 8-K current report announcing the earnings release and presentation, and the actual financial data is in the attached press release and presentation, the best classification is Earnings Release (ER).
2025-05-08 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.